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ABSTRACT
Aims To identify different types of models used in economic evaluations of smoking cessation, analyse the quality of the
included models examining their attributes and ascertain their transferability to a new context.Methods A systematic re-
view of the literature on the economic evaluation of smoking cessation interventions published between 1996 and April
2015, identified via Medline, EMBASE, National Health Service (NHS) Economic Evaluation Database (NHS EED), Health
Technology Assessment (HTA). The checklist-based quality of the included studies and transferability scores was based on
the European Network of Health Economic Evaluation Databases (EURONHEED) criteria. Studies that were not in smoking
cessation, not original research, not amodel-based economic evaluation, that did not consider adult population and not from
a high-income country were excluded. Findings Among the 64 economic evaluations included in the review, the state-
transition Markov model was the most frequently used method (n = 30/64), with quality adjusted life years (QALY) being
the most frequently used outcome measure in a life-time horizon. A small number of the included studies (13 of 64) were
eligible for EURONHEED transferability checklist. The overall transferability scores ranged from 0.50 to 0.97, with an average
score of 0.75. The average score per section was 0.69 (range = 0.35–0.92). The relative transferability of the studies could
not be established due to a limitation present in the EURONHEEDmethod.Conclusion All existing economic evaluations in
smoking cessation lack in one or more key study attributes necessary to be fully transferable to a new context.
Keywords Economic evaluation, modelling, smoking, systematic review, tobacco, transferability.
Correspondence to: Subhash Pokhrel, Health Economics Research Group (HERG), Institute of Environment, Health and Societies, College of Health and Life
Science, Brunel University London, Kingston Lane, Uxbridge UB8 3PH, UK. E-mail: subhash.pokhrel@brunel.ac.uk
Submitted 22 February 2016; initial review completed 6 June 2016; final version accepted 30 December 2016
INTRODUCTION
The core strategies in reducing smoking prevalence are to
prevent people from starting smoking, to reduce the num-
ber of smokers and to decrease the chances of relapse. This
can be achieved by implementing population-based to-
bacco control policies (e.g. legislations and mass media
campaigns) and smoking cessation programmes (e.g. drug
or behavioural therapies) targeted at current smokers.
However, due to the increasing number of interventions
now available, decision-makers face difficulties in deciding
which intervention to implement. Given scarce resources,
relative costs and benefits of those interventions are one
of the key decision-making criteria, thusmaking the impor-
tance of economic evaluations rise in recent years [1,2].
Economic evaluations combine the outcomes of inter-
ventions with their costs, in order to determine which in-
tervention provides the best value for money [3]. Such
evaluations, for example, have shown that treatment with
varenicline [4,5] or behavioural support by mobile phone
[6] can be cost-effective. Model-based economic evalua-
tions are especially appropriate to extrapolate the benefits
beyond clinical trials and when a single primary source of
data is not sufficient [7]. In addition, a model-based eco-
nomic evaluation has the ability to adapt itself to a new
context, making the process of executing economic evalu-
ations less time-consuming and thus less costly [8,9]. Un-
fortunately, such evaluations often originate in affluent
societies. The number of lives that can be saved from the
use of such evidence elsewhere (e.g. countries in Central
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and Eastern Europe) is potentially enormous. Sadly, those
countries often have too limited research resources to
study cost-effectiveness of such interventions in their own
context, highlighting the importance of transferability
assessments [9,10].
The notion of transferability of evidence from one con-
text to others varies widely in the literature. ‘Transferabil-
ity’, ‘generalizability’ and ‘external validity’ are the
concepts used to assess the ability of a study to be relevant
to the decision maker’s context to the extent the findings
could actually be used [11–15]. However, a distinction also
exists between what is feasible/applicable and what is
generalizable/transferable. Applicability refers to ‘how can
I replicate the intervention in my own decision context?’
(the process question) and generalizability refers to
‘whether the effectiveness will be similar to that in the orig-
inal context?’ (the outcome question) [12,13,15,16].
Therefore, these two underlying questions seem to have
defined transferability in the literature.
Transferability assessments to date have focusedmainly
on the way inwhich amodel is constructed and populated,
as modelling provides awell-defined structure helping us to
recognize the limitations and their implications for general-
izability of the results [7,17–19]. There has not been a sys-
tematic enquiry in to the transferability of economic
evaluations in smoking cessation, although a few system-
atic reviews in this area exist [20,21]. The review by Kirsch
et al. [21], for instance, limits itself to a narrow definition of
study population and to a specific type of economic model.
In this paper, we therefore set out to: (i) identify different
types of models used in economic evaluations of smoking
cessation; (ii) analyse the quality of the included models
examining their attributes; and (iii) ascertain their trans-
ferability to a new context.
METHODS
Search strategy and implementation
A systematic search was conducted to identify all relevant
models used for economic evaluation in smoking cessation
on the following databases: National Health Service (NHS)
Economic Evaluation Database (NHS EED), Health Tech-
nology Assessment (HTA), Medline and EMBASE. They
were searched for publications in English language be-
tween 1996 and April 2015. The search strategy was
based on related published systematic reviews [20,22–24],
leading to the final search terms ‘smoking’, ‘nicotine’ and
‘tobacco’ in NHS EED and HTA. Medline and EMBASE
required additional terms related to model-based economic
evaluation, which were based onWilczynski et al. [25] and
McKinlay [26] to acquire high sensitivity as well as high
specificity [27]. Supporting information, Table S1 shows
an overview of the search strategies used by databases.
All results were exported to EndNote (Thomson Reuters)
version X7, where duplications were removed automati-
cally and remaining duplicates checked manually.
Exclusion criteria and screening
Title and abstract screening for the first 50 papers was per-
formed independently by two reviewers (M.H. and M.B.)
based on the following exclusion criteria: (1) topic not in
smoking cessation (as the focus was on the interventions
to reduce tobacco use), (2) no original research (to avoid in-
clusion of review of evidence or opinion pieces), (3) no
model-based economic evaluation (to avoid inclusion of
other designs, e.g. trial-based evaluations), (4) no adult gen-
eral population (to focus on adults, rather than children),
(5) no high-income country (to reduce study heterogeneity
by including comparable, industrialized countries based on
their income levels) and (6) not available in the English
language (practicality reasons mainly to address resource
constraints). No differences in exclusion/inclusion were ob-
served between both reviewers; only minor discrepancies
were recorded in the reason of exclusion. The inter-rater
reliability (IRR) gave a Cohen’s kappa of 0.912, meaning
almost perfect agreement [28]. Remaining discrepancies
were discussed, leading to full agreement. Screening of the
remaining papers was then completed by one researcher
(M.B.). Full text screening was performed independently
by two reviewers (M.B. andK.L.C. orM.H.). Therewere only
minor discrepancies between the reviewers, which led to
full agreement after discussion. Supporting information,
Tables S2 and S3 show an extended list of exclusion criteria
for full-text screening.
Data extraction
Data on the following items were extracted using an Excel
template adapted from published studies [20,29,30] and
included: study attributes (type of evaluation, interven-
tions, comparator and country); model (type, transition
or health states, time horizon and perspective); effective-
ness (outcome and discount rate, primary measure of
effectiveness and utility valuations); costs (perspective,
categories, resource, index year and discount rate); uncer-
tainty (type and outcome of sensitivity analysis); and
results and major limitations.
As data from some included studies were already
extracted by the University of York’s Centre for Reviews
and Dissemination (CRD) (n = 39 of 64), only one
researcher (M.B.) extracted data independently on those
studies and compared with the CRD extraction. The CRD
database contains clear and structured summaries of the
economic analyses by experts, and therefore it was deemed
sufficient to compare the results of data extraction to these
summaries. For the remaining studies that were not
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included in the CRD database, the data were extracted
independently by two reviewers (M.B. and one of the
following: M.H., K.L.C., R.D.K. and P.K). Any disagreement
between the reviewers was resolved by consensus with a
third reviewer.
Quality appraisal
In order to appraise the quality, 10% of the included studies
were first assessed independently byM.B. andM.H., using a
quality checklist and corresponding classification from the
National Institute for Health and Care Excellence (NICE)
Methodology Guide with the aim to filter out quality-poor
studies [31]. The quality checklist was based on three
major criteria: (1) the studywas conducted from a relevant
perspective (i.e. at least payer or health-care perspective;
(2) the study was a cost–utility or cost–benefit analysis
with cost/quality adjusted life years (QALY) or benefit–cost
ratio reported; and (3) limitations, either stated in the orig-
inal study or identified by the reviewers during data extrac-
tion stage. Once the overall assessment using these criteria
was completed, the studies were assigned to one of the
following three classifications: (i) a study with minor limi-
tations (ML); (ii) a studywith potentially serious limitations
(PSL); or (iii) a studywith very serious limitations (VSL). As
full agreement on quality classification was reached in the
10% of the included studies, M.B. then completed the
quality appraisal of the remaining studies.
Transferability assessment
The studies appraised as the one with minor limitations
(ML) were considered to be of sufficient quality to be
included for transferability assessment applying the
EURONHEED checklist [9]. Two independent researchers
(M.B. and one of the following: M.H., K.L.C., R.D.K. and P.
K.) applied the checklist. The EURONHEED checklist was
developed originally by Boulenger et al. [9] and described
and updated further with guidelines by Nixon et al. [32].
It consists of 42 questions, 26 of which relate to overall
methodological quality and internal validity, and 16 ques-
tions relate to transferability. An overview of all questions
is provided in Supporting information, Table S4. Every
question can be answered by ‘yes/partially/no or not appli-
cable (NA)’, assigning a score of 1, 0.5 and 0, respectively.
While each item in the checklist is treated equally (but im-
plicitly giving more weight to 16 of the 42 items), the
assigned score to each question thus additionally provides
another weight to reflect the extent to which each item
was reported in the study being assessed [32]. The combi-
nation of the questions generates an overall summary
score [9,10]. We calculated two summary scores: the total
summary score including all 42 items and the transferabil-
ity score including the 16 items. The summary scores were
calculated using the following formula; 1nx∑iSi100 , in
which n is the number of questions, x is the number of
questions for which the response was NA and S is the score
of each question [9]. The summary scores reflect how
thoroughly key methodological items are reported as
the quality of reporting is paramount for generalizability/
transferability [32]. In addition to this, we calculated the
scored percentage of the total score possible per section.
This showed us what sections within model-based
economic evaluations were of sufficient quality and
which needed further improvement. For example, a score




The systematic literature search yielded 1925 references.
After removing duplicates, 1500 studies were included
for title and abstract screening which led to a total of 101
studies selected for full text screening. On applying the
exclusion criteria, 64 studies were judged to be eligible for
data extraction. Thirteen of the 64 studies were included
for transferability assessment. An overview of the process
is provided in Fig. 1.
Overview of studies
An overview of the identified models is shown in Table 1.
Most studies originated from Europe (n = 30 of 64) and
the United States (n = 24 of 64), followed by Australia
(n = four of 64) and Asia (n = two of 64). Three of 64
studies were multi-continental.
The populations in the analyses were described mainly
as the general adult population of smokers. In three studies
the populations were described further as smoking 20 cig-
arettes per day or more [33–35], making or considering a
single or first quit attempt [36–39] or had recently tried
to quit smoking [40,41]. In five studies the population
was described only as a dynamic and/or hypothetical
cohort [42–46] and in nine studies the population was
not reported at all [47–55].
A significant part of the intervention was
smoking cessation programmes, either pharmacotherapy
[4,5,36–38,40,41,48,50,51,53,55–65], behavioural ther-
apy [6,42,47,66–69] or a combination of these [33–
35,43,45,46,49,52,54,70–75]. Several studies evaluated
wider tobacco control interventions [39,44,76–88],
whereas five studies included both smoking cessation
programmes and tobacco control interventions [89–93].
In a number of studies, the authors selected ‘no inter-
vention’ or ‘current situation’ as comparator. All other
studies described the comparators in more detail (Table 1).
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The main measure of outcome used is the QALY.
In total, 23 of 64 studies reported QALY as their
main outcome [5,35,38,40,41,47–49,56,58,59,61–
63,65,69,70,76,78,81,86,88,94], followed by life years
(LY) gained (n = nine of 64) [33,43,46,66–68,73,74,89]
or a combination of these (n = 12 of 64) [4,6,35–
37,39,42,44,57,77,80,83]. Five of 64 studies reported dis-
ability adjusted life years (DALY) as their main outcome
[60,82,90–92], and only four of 64 (incremental) net ben-
efit [52,53,55,71]. There were two of 64 studies reporting
only the intermediate outcomes of the intervention
[85,93] (Table 1).
Overview of economic models
Table 2 shows the main model attributes used in the
included studies. Thirty of 64 studies used aMarkovmodel,
12 of which used a specific type called the benefits of
smoking cessation on outcomes (BENESCO) model
[4,5,36,37,48,56–59,61,62,65]. Decision-tree models
[41,43,52,55,63,71,75,83,93], discrete-event simulations
(DES) [45,54], the chronic disease model (RIVM-CDM)
[44,81,88], the tobacco policy model (TPM) [76,77], the
quit benefits model (QBM) [80], the World Health Orga-
nization (WHO) model [90], the global health outcomes
model (GHO model) [70] and the abstinent-contingent
treatment model (ABT model) [73] were also used.
Twelve of 64 studies did not report explicitly the model
used, reporting only decision analysis modelling or simu-
lation modelling [39,50,51,66,69,72,74,78,86] or limit-
ing the description to only dynamic or static modelling
[42,82,92].
Several (18 of 30) studies based on Markov models pro-
vided sufficient information on transition or health states
used in the model. The most frequently used transition
states were current smoker, former smoker or death, while
health states included asthma exacerbation, coronary
heart disease (CHD), stroke, chronic obstructive pulmo-
nary disease (COPD) and lung cancer. In decision-tree
models (n = nine of 64) the most reported transition states
were quit attempt or no quit attempt, often combined with
success to quit or failure to quit.
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram, based on National Health Service
Economic Evaluation Database (NHS EED) and Health Technology Assessment Database (HTA). [Colour figure can be viewed at
wileyonlinelibrary.com]
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The majority of the Markov models used a life-time
horizon (n = 22 of 30) while decision-tree models consid-
ered a time between 1 and 50 years. Most of the studies
based on other models lacked sufficient information, or
reported a time-horizon of 50 years. Most evaluations
used a health-care and/or payer perspective (n = 50 of
64). Twelve of 64 used a societal perspective. The re-
ported primary measure of effectiveness in all models
was quit rate or its variants (e.g. continuous abstinence
rates).
The majority of the studies (n = 55 of 64) performed
sensitivity analyses to account for uncertainties in their
estimates. Markov model-based studies performed mainly
both univariate and probabilistic sensitivity analyses,
decision-tree models used univariate sensitivity analyses
often in combination with multivariate sensitivity analy-
ses (n = five of nine), and the other models (n = 25 of
64) conducted univariate sensitivity analyses (n = 13
of 25).
Quality assessment and transferability
Of the 64 included studies assessed for quality, 15 were
excluded based on the first criteria (no health-care perspec-
tive), 12 based on the second (no cost benefit or cost–utility
analysis) and 24 on the final criteria (having major limita-
tions). As shown in Table 3, 13 of 64 studies were then
classified as having minor limitations, 35 as having poten-
tially serious limitations and 16 as having very serious
limitations.
Table 4 provides an overview of the scoring per ques-
tion on the EURONHEED checklist for the 13 studies
judged as having sufficient quality including the summary
scores. The studies’ total scores varied between 57 and
87% and the scores of the transferability checklist from
50 to 97%.
The average score per section presented as the percent-
age of the total score are shown in Fig. 2. The average score
per section was 0.69 (range = 0.35–0.92). The sections
that scored below the average (69%) were: health technol-
ogy assessment study population, effectiveness, benefit
measure, variability and generalizability.
DISCUSSION
Key findings
Markov-based state transition models with QALY as the
outcomemeasurewere themost frequently used technique
in evaluating the cost-effectiveness of smoking cessation in-
terventions. However, the majority of the studies were re-
ported poorly, making it hard to assess their
transferability using the existing checklist-based method.
Where such assessment was possible, studies showed a
wide variation in transferability scores, driven mainly by
the method of selecting populations, assessing effectiveness
and outcomes and estimating variability and generalizabil-
ity of their own findings.
Relative transferability
The EURONHEED method assumes that without a quality
score it would be impossible to transfer a study to another
setting [9,32,95]. Therefore, the explicit assessment using
this method resulted in some studies being more
favourable candidates than others. However, on average,
all studies lacked in some attributes for full transferability.
One of the main differences between a high score and a
low score is how differently the studies scored on the
questions on costs. For example, Annemans et al.
(2009), with a score of 0.50, addressed most of the cost
questions only partially, whereas Hoogendoorn et al.
(2008), with a score of 0.97, did so fully. Therefore, costs
are important determinants of the transferability assess-
ment [9]. Our review also highlighted other determinants;
namely, selection of study population, intervention and
comparator descriptions, effectiveness and benefit mea-
sures and variability/generalizability analyses—all scoring
below the overall average score. Without a threshold, it
Table 3 Results of the quality assessment.
Classification Studies
Minor limitations Annemans, 2015; Annemans, 2009; Athanasakis, 2012; Bolin, 2006; Bolin, 2008; Bolin, 2009b; Boyd, 2009;
Cornuz, 2003; Guerriero, 2013; Hoogendoorn, 2008; Howard, 2008; Over, 2014; Stapleton, 1999
Potentially serious
limitations
Ahmad, 2005a; Ahmad, 2005b; Bae, 2009; Bauld, 2011; Bolin, 2009a; Brown, 2014; Cantor, 2015;
Chevreul, 2014; Cornuz, 2006; Feenstra, 2005; Fiscella, 1996; Halpern, 2007b; Heitjan, 2008; Hill, 2006;
Hojgaard, 2011; Hurley, 2008; Igarashi, 2009; Linden, 2010; Levy, 2002; Nohlert, 2013; Ong, 2005;
Pinget, 2007; Shearer, 2006; Simpson, 2013; Song, 2002; Stapleton, 2012; Taylor, 2011; Tran, 2002; Van
Baal, 2007; Vemer, 2010a; Vemer, 2010b; VonWartburg, 2014;Warner, 1996;Welton, 2008; Xenakis, 2009
Very serious
limitations
Bertram, 2007; Croghan, 1997; Dino, 2008; Halpern, 2007a; Knight, 2010; Lai, 2007; Lal, 2014; Levy, 2006;
McGhan, 1996; Nielsen, 2000; Olsen, 2006; Ranson, 2002; Van Genugten, 2003; Xu, 2014; Jackson, 2007;
O’Donnell, 2011
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was not possible to rank the assessed studies on their
relative transferability, and this will be explored further
below.
Comparison to current literature
Several systematic reviews are available on the cost-
effectiveness of smoking cessation [22–24], but only one
systematic review looking at model-based economic eval-
uations [20]. Most of the studies included in their review
used the Markov model with long-term time horizons,
included comparable health states and reported the simi-
lar measures of effectiveness and outcomes as ours, and
common weaknesses included poor reporting of the
modelling details. However, a key difference from our
review is that they did not build on their findings to
evaluate the extent to which such models could be
transferable from the original context to others, for wider
benefits [9,10,17]. In areas outside smoking cessation,
Korber has evaluated physical activity interventions for
their transferability [96]. Consistent with our findings,
she also found that a very few included studies explored
variability from place to place and discussed caveats
regarding the generalizability of results, ‘leading to a wide
variation in the transferability of the study results ranging
from “low” to “very high” with everything in between’
[96]. Another study [97] found that population and
methodological characteristics were poorly reported—a
finding that echoes our own results on the weaknesses
of the models.
Implications of this review
Despite the availability of several guidelines on how to con-
duct and report adequately on economic evaluations
[29,31], there is still a considerable variation in the quality
of published economic evaluations in smoking cessation.
Arguably, this may limit the use of such evidence in other
contexts. Some authors argue that the factors affecting
the perception of applicability (the process question) and
transferability (the outcome question) together might be
broader than the factors associated with external validity
[13]. Notwithstanding this difference, the EURONHEED
method relies heavily upon the quality of reporting to as-
certain transferability [32]. Therefore, such scores can be
limited in use by the end-users for two reasons. First, a
poorly constructed model could have been reported well
scoring high on the transferability scale and vice versa.
Secondly, without a threshold score, it is hard to judge a
study or to rank and compare across the studies. Nixon
et al. [32] argue that the EURONHEED score should, rather,
be used as a general guide in making decisions, but also
note that the explicit assessment of transferability using
thismethodwill introduce an educational element, helping
researchers to improve the design, conduct and reporting
of future studies.
This review highlights the educational element noted
above. Transparency in themodel building and subsequent
analysis and results, which can be captured by the quality
of reporting, can enhance our understanding of the under-
lying process and outcome questions. However, a robust
method would require more analyses based on the model
Figure 2 Percentage of total score per section. Calculated as the average of the% of total score of subitems. [Colour figure can be viewed at
wileyonlinelibrary.com]
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outputs (as opposed to the checklists), backed up by the
perceptions of actual stakeholders (including decision
makers) as to what is relevant, adaptable, valid and trans-
ferable to them [13,16]. The European study on Quantify-
ing Utility of Investment in Protection from Tobacco
(EQUIPT) [98] provides some promise to that end by
encompassing both model-based analyses (e.g. on the
parameter importance and variability) and the analysis of
the stakeholder views (e.g. on the importance of interven-
tions and intention to use economic evidence in
policymaking) [99,100], in addition to the systematic
reviews based on the published models such as this.
Although the final results of the EQUIPT study are yet to
be published, this comprehensive framework appears to
provide the end-users with an understanding of a key
transferability attribute—what changes in the economic
model would make it transferable to their own settings
and why [15].
This review also reiterates the already identified chal-
lenge in terms of the way in which economic evaluations
in broader public health are designed, conducted and
reported [101]. The finding that only one-fifth of the
included study met quality classification for transferability
implies that policymakers, researchers and journal editors
need towork together in enhancing the quality of new eco-
nomic evaluations and making it more transferable. The
guidelines used by economic evaluation community and
journals such as this are helpful to that end [102]. How-
ever, such guidelines should also emphasize the need for
the authors to assess and report transferability of their
models to the new contexts. This would ensure that future
studies could consider adding model-based analysis of
transferability on to the checklist-based evaluation, backed
up by, where possible, analysis of the views of stakeholders.
Limitations
A major limitation of this review has been the limitation
embedded in the existing method of transferability assess-
ment [9,32]. Future researchmay overcome this limitation
by adopting a comprehensive assessment as discussed
above. In addition, limiting the search to English language
only might have excluded some studies. However, we iden-
tified more model-based economic evaluations than a pre-
vious similar review [22]. The use of three quality criteria
[31] for inclusion of studies in the transferability assess-
ment could potentially have introduced some bias, as it
was based on the overall assessment, as opposed to some
standard checklists such as those by Drummond [103] or
Philips [104]. However, the variety of items included in
our data extraction form as outlined in the best practice
guidelines [102] were very similar to the Drummond or
Philips checklists, implying the possibility of such bias to
be minimal. Finally, exclusion of low-/middle-income
countries to reduce study heterogeneity could have limited
this review in its primary focus (i.e. evidence transferability
to less-affluent countries).
CONCLUSION
Existing economic evaluations in smoking cessation vary
in quality, resulting mainly from the way in which they
selected their populations, measured costs and effects and
assessed the variability and generalizability of their own
findings. All studies lacked one ormore key study attributes
for full transferability. A robust design, coupled with com-
prehensive reporting of key study attributes, could make
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